Companies Related to "Pathologic assessment gastrointestinal tract pancreatic carcinoma after neoadjuvant" [Most Relevant Company Matches] RSS

10:07 EST 23rd November 2017 | BioPortfolio

Here are the most relevant search results for "Pathologic assessment gastrointestinal tract pancreatic carcinoma after neoadjuvant" found in our extensive corporate database of over 50,000 company records.

Showing "Pathologic assessment gastrointestinal tract pancreatic carcinoma after neoadjuvant" Companies 1–25 of 622

Monday 20th November 2017

resTORbio, Inc.

resTORbio, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for the treatment of aging-related diseases. resTORbio’s lead program is targeting the target of rapamycin complex 1 (TORC1) pathway to treat aging-related diseases and conditions with an initial focus on conditions caus...

Wednesday 8th November 2017

Jaguar Health, Inc.

Jaguar Health, Inc. is a natural-products pharmaceuticals company focused on developing and commercializing novel, sustainably derived gastrointestinal products for both human prescription use and animals on a global basis. Our wholly-owned subsidiary, Napo Pharmaceuticals, Inc., focuses on developing and commercializing proprietary human gastrointestinal ...

Tuesday 7th November 2017

Progenity Inc.

Progenity is a biotechnology company with a market-leading presence in Women’s Health molecular testing and a pipeline of proprietary tests and therapeutic applications under development. Progenity has a portfolio of innovative technologies and tests for pre-eclampsia, genetic carrier testing, inheritable cancer genetics, liquid biopsy and noninvasive ...

Monday 6th November 2017

Alcresta Therapeutics, Inc.

Alcresta Therapeutics, Inc. is dedicated to developing and commercializing novel enzyme-based products designed to treat gastrointestinal disorders and rare diseases. The company uses its proprietary technology platform to support a broad pipeline of products, with an initial focus on pancreatic insufficiency, which results in malabsorption common in cysti...

Tuesday 24th October 2017

Translational Drug Development (TD2) and Minneamrita Therapeutics LLC

Minneamrita is an early clinical stage drug development company developing the molecules for unmet cancer treatments. Minneamrita is developing Minnelide for its use in various cancers (gastric, pancreatic, breast and AML).

Tuesday 17th October 2017

DNV GL Healthcare

DNV GL is a world-leading certification body. We help businesses assure the performance of their organizations, products, people, facilities and supply chains through certification, verification, assessment, and training services. Within healthcare we help our customers achieve excellence by improving quality and patient safety through hospital accreditati...

Monday 2nd October 2017

National Breast Center

National Breast Center located in Alexandria, VA is founded by David Weintritt MD, a board certified breast surgeon. The National Breast Center provides a comprehensive program for early detection, diagnosis, and treatment of breast cancer, as well as services for those at high risk for breast cancer. The Breast Center combines advanced technology and over...

Thursday 28th September 2017


Savonix delivers the world's first fully mobile, evidence-based assessment of cognitive function. Available on Android and iOS for phone and tablet, Savonix Mobile is an accurate, accessible and affordable tool for professional cognitive screening. It empowers healthcare providers, payers and researchers to evaluate and leverage results to improve health a...

Tuesday 26th September 2017

Synergys Biotherapeutics

Synergys is an early stage company developing multifunctional anti-vascularization antibody drugs targeting VEGF-alternative pathways. The Company’s most advanced product candidate, Anti-EGFR‐TAP (SYN001) was derived from its platform technology termed A‐TAP (Antibody-Targeted Anti-Vascularization Payload). SYN001 is currently in preclinical ...

Monday 25th September 2017

NewLink Genetics Corporation

NewLink Genetics Corporation is a biopharmaceutical company developing novel drugs and functional genomics solutions with a primary focus on cancer.The successful completion of the Human Genome Project signals a new age in medical discovery centered on protein research. The rapidly growing knowledge base of the human genome provides an unprecedented opportunity to launch a revolutionary paradigm ...

Gelesis, Inc.

Gelesis100 is a new approach to weight loss that is designed to employ multiple mechanisms of action along the GI tract to promote satiety and induce weight loss. Gelesis100 is non-systemic and administered orally in capsules containing small hydrogel particles, which are made from two naturally-derived ingredients that compose a novel 3D matrix. The novel ...

Friday 8th September 2017


Quidel Corporation discovers, develops, manufactures and markets rapid immunodiagnostic products for point-of-care detection of human medical conditions and illnesses. These products provide simple, accurate and cost-effective diagnoses of acute and chronic conditions in the areas of reproductive and women's health, infectious diseases, gastrointestinal andautoimmune disorders. Quidel's products a...

Friday 1st September 2017

Can-Fite BioPharma Ltd.

Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE: CFBI) is an advanced clinical stage drug development Company with a platform technology that is designed to address multi-billion dollar markets in the treatment of cancer, inflammatory disease and sexual dysfunction. The Company's lead drug candidate, Piclidenoson, is scheduled to enter Phase III trials in 2...

Wednesday 23rd August 2017

GI Dynamics

GI Dynamics is focused on developing effective, non-surgical approaches for treating type 2 diabetes and obesity. The company’s patented EndoBarrier™ Technology has the potential to deliver medical interventions for patients combating weight problems and diabetes or diabetes risk factors. Data from clinical trials demonstrate that the EndoBarr...

Monday 21st August 2017

Anatara Lifesciences

Anatara Lifesciences is developing therapeutics for gastrointestinal diseases in production animals and humans. Its lead product Detach® is a natural plant based product that will help address global concerns around the overuse of antibiotics in production animals that is contributing to the rise of so-called “super bugs” that make infectious ...

Wednesday 2nd August 2017


Zensights is a pharmaceutical vendor management company focused on making the currently complex world of vendor selection easier for the BioPharma manufacturer. Zensights' signature Vendor Analysis Tool analyzes, aggregates, and provides an overall market assessment of the capabilities of third-party vendors that service the bio-tech, pharmaceutical,...

Wednesday 19th July 2017


iProcedures provides software solutions to streamline the perioperative workflow. iProcedures bridges gaps in current enterprise workflow by providing innovative technology solutions, which increase productivity and provide effective, focused, clinical care. iProcedures offers a wide range of specialty-specific products, including a pre-op anesthesia asses...

Wednesday 14th June 2017

CellMax Life

CellMax Life, Inc. is a precision cancer blood-testing company providing comprehensive, personalized multi-biomarker technology platforms for genetic cancer risk assessment, early detection and personalized treatment of cancer. CellMax Life’s products include CellMax-DNA Genetic Cancer Risk Test, CellMax-LBx Liquid Biopsy, and CellMax-CRC Colorectal C...

Thursday 1st June 2017

ColonaryConcepts, LLC

ColonaryConcepts, LLC, headquartered in Newton, MA, is committed to developing patient-centric innovations that improve gastrointestinal health. The company currently has one product candidate in clinical development: C-Bar™, a novel treatment for chronic constipation, which is currently being studied in a Phase 1b clinical trial. ColonaryConceptsâ€...

Wednesday 10th May 2017

CEL-SCI Corporation CEL-SCI Corporation

CEL-SCI's work is focused on finding the best way to activate the immune system to fight cancer and infectious diseases. Its lead investigational immunotherapy, Multikine* (Leukocyte Interleukin, Injection), is currently being studied in a pivotal Phase 3 clinical trial as a potential neoadjuvant treatment for patients with squamous cell carcinoma of the h...

Tuesday 9th May 2017

Commonwealth Diagnostics International, Inc.

Commonwealth Diagnostics International, Inc. is an international diagnostic service provider specializing in cutting-edge diagnostic products that assist physicians and patients with the diagnosis of some of the common sources of digestive distress and functional gastrointestinal disorders. CDI’s current diagnostic portfolio (excluding R&D) specialize...

Aravive Biologics, Inc.

Aravive Biologics is a privately held, late pre-clinical stage biopharmaceutical company developing novel, highly selective cancer therapies that treat serious malignancies while sparing normal healthy cells. The company’s lead program is focused on the GAS6/AXL pathway, where activation appears to play a critical role in multiple types of cancer mali...

Tuesday 2nd May 2017

Aries Pharmaceuticals, Inc.

Aries Pharmaceuticals, Inc. (Aries) is a specialty pharmaceutical company commercializing best-in-class gastroenterology products for the United States market with a focus on products utilized in endoscopy and for the treatment of specific gastrointestinal diseases. The company’s initial portfolio of four products, three of which are still in devel...

Thursday 20th April 2017

World Pancreatic Cancer Coalition

The World Pancreatic Cancer Coalition is an international group of pancreatic cancer patient advocacy groups with a mission to drive transformational change for all those affected by the disease. Through global collaboration, the coalition raises awareness of pancreatic cancer by strengthening the efforts of participating member organizations. Each Novembe...

Monday 10th April 2017


Prometric, a wholly-owned subsidiary of ETS, is the recognized global leader in technology-enabled testing and assessment services. Its comprehensive suite of services, including test development, test delivery and data management capabilities, allows clients to develop and launch global testing programs as well as accurately measure program results and da...

More From BioPortfolio on "Pathologic assessment gastrointestinal tract pancreatic carcinoma after neoadjuvant"

Quick Search

Corporate Database Quicklinks